Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.
Russell J. Schilder, MD
Advertisement
Articles by Russell J. Schilder, MD
Advertisement
Latest Updated Articles
Dr. Schilder on PARP Inhibitors in Gynecologic CancersPublished: October 22nd 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5